Kyron.Bio

Kyron Bio uses an innovative cell line engineering approach to unlock precision control of glycosylation patterns on therapeutic proteins. This breakthrough technology addresses several industry challenges, including reduction of antibody immunogenicity, enhancement of the drug's half-life, and improvement in the antibody production QC process, to name a few. Furthermore, their platform could play a major role in optimizing the manufacturing of Antibody-Drug Conjugates (ADCs) by enabling improved conjugation rates.
Founders / Management Dr. Emilia McLaughlin
Sectors Health & Bio
Located in Paris, France
Co-Investors HCVC, Entrepreneurs First, Saras Capital
Follow On

LinkedIn

Sign up to receive our regular newsletter and learn about investing in technologies that are changing the world.

Privacy Preference Center